Seattle Genetics, Inc.

( )
SGEN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 7.99%74.480.0%$2392.34m
NVAXNovavax, Inc. 0.96%150.9299.2%$1183.33m
SRNESorrento Therapeutics, Inc. -3.19%13.641.5%$726.10m
GILDGilead Sciences, Inc. 0.69%68.571.0%$570.47m
AMGNAmgen, Inc. 0.04%234.751.3%$473.32m
REGNRegeneron Pharmaceuticals, Inc. 0.52%602.002.7%$397.05m
BNTXBioNTech SE 4.09%71.250.0%$378.73m
VXRTVaxart, Inc. 1.02%10.860.0%$363.16m
VRTXVertex Pharmaceuticals, Inc. 0.05%262.001.9%$360.14m
BIIBBiogen, Inc. 0.45%291.251.6%$355.70m
ILMNIllumina, Inc. 0.11%341.583.5%$333.07m
ATNMActinium Pharmaceuticals, Inc. 4.46%10.0813.3%$247.01m
EBSEmergent BioSolutions, Inc. 2.28%125.006.4%$179.75m
ALXNAlexion Pharmaceuticals, Inc. 0.11%101.352.0%$165.09m
SGENSeattle Genetics, Inc. 0.57%154.366.2%$156.35m

Company Profile

Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.